Trifluoroacetate (TFA) Counterion
The trifluoroacetate counterion is the salt form most synthetic peptides carry after acidic cleavage and reversed-phase purification, contributing several percent or more of the powder's mass.
Synthetic peptides come off the resin under strong acid and are purified in trifluoroacetic-acid-modified mobile phases, so basic sites such as lysine and arginine side chains, histidine, and the free N-terminus end up protonated and paired with trifluoroacetate anions. The isolated powder is consequently a trifluoroacetate salt, and how much of it there is scales with the number of basic sites, commonly running from a few percent to well above ten percent by weight.
Approved injectable peptides generally do not ship in this form. Products such as leuprolide acetate, octreotide acetate and glucagon name their salt within the drug name, and manufacture includes a counterion exchange performed by ion-exchange chromatography or by repeated lyophilisation from dilute acetic acid, followed by an assay confirming residual trifluoroacetate. Trifluoroacetate is also cytotoxic to cultured cells at concentrations that are easy to reach in vitro.
The counterion changes the powder, not the molecule. The peptide cation is identical either way, so receptor pharmacology is unchanged, but mass is not: two vials with the same milligram figure on the label deliver different quantities of peptide when their salt forms differ. In cell work the difference exceeds bookkeeping, because carried-over trifluoroacetate can suppress viability and be misattributed to the test compound.
Two things deserve attention. Trifluoroacetate-free is a claim that requires a counterion assay to mean anything, and certificates make it far more often than they report a number. And counterion load is one of the reasons chromatographic purity and net peptide content diverge, since the counterion contributes nothing to the ultraviolet trace that generates the purity figure while contributing substantially to the mass on the balance.